JP2022513098A - 体重減少及び/又は食物摂取量低減に使用するためのgdf15類似体及び方法 - Google Patents

体重減少及び/又は食物摂取量低減に使用するためのgdf15類似体及び方法 Download PDF

Info

Publication number
JP2022513098A
JP2022513098A JP2021527918A JP2021527918A JP2022513098A JP 2022513098 A JP2022513098 A JP 2022513098A JP 2021527918 A JP2021527918 A JP 2021527918A JP 2021527918 A JP2021527918 A JP 2021527918A JP 2022513098 A JP2022513098 A JP 2022513098A
Authority
JP
Japan
Prior art keywords
dose
administered
fusion protein
study
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2021527918A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022513098A5 (https=
Inventor
ジャン,ソンマオ
キムコ,ホリー
ヘルマン,ロバート
ファブリニ,エリサ
ストヤノビッチ-ススリック,ヴェドラナ
ローゼンバーグ,ポール
Original Assignee
ヤンセン ファーマシューティカ エヌ.ベー.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヤンセン ファーマシューティカ エヌ.ベー. filed Critical ヤンセン ファーマシューティカ エヌ.ベー.
Publication of JP2022513098A publication Critical patent/JP2022513098A/ja
Publication of JP2022513098A5 publication Critical patent/JP2022513098A5/ja
Priority to JP2025019347A priority Critical patent/JP2025081388A/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • C07K14/495Transforming growth factor [TGF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76Albumins
    • C07K14/765Serum albumin, e.g. HSA
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/20Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/31Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
JP2021527918A 2018-11-20 2019-11-19 体重減少及び/又は食物摂取量低減に使用するためのgdf15類似体及び方法 Withdrawn JP2022513098A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025019347A JP2025081388A (ja) 2018-11-20 2025-02-07 体重減少及び/又は食物摂取量低減に使用するためのgdf15類似体及び方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862769675P 2018-11-20 2018-11-20
US62/769,675 2018-11-20
PCT/IB2019/059945 WO2020104948A1 (en) 2018-11-20 2019-11-19 Gdf15 analogs and methods for use in decreasing body weight and/or reducing food intake

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025019347A Division JP2025081388A (ja) 2018-11-20 2025-02-07 体重減少及び/又は食物摂取量低減に使用するためのgdf15類似体及び方法

Publications (2)

Publication Number Publication Date
JP2022513098A true JP2022513098A (ja) 2022-02-07
JP2022513098A5 JP2022513098A5 (https=) 2022-11-25

Family

ID=70773869

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021527918A Withdrawn JP2022513098A (ja) 2018-11-20 2019-11-19 体重減少及び/又は食物摂取量低減に使用するためのgdf15類似体及び方法
JP2025019347A Pending JP2025081388A (ja) 2018-11-20 2025-02-07 体重減少及び/又は食物摂取量低減に使用するためのgdf15類似体及び方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025019347A Pending JP2025081388A (ja) 2018-11-20 2025-02-07 体重減少及び/又は食物摂取量低減に使用するためのgdf15類似体及び方法

Country Status (15)

Country Link
US (1) US20220315633A1 (https=)
EP (1) EP3883960A4 (https=)
JP (2) JP2022513098A (https=)
KR (1) KR20210094584A (https=)
CN (2) CN113474363A (https=)
AU (2) AU2019383019A1 (https=)
BR (1) BR112021009225A2 (https=)
CA (1) CA3120236A1 (https=)
EA (1) EA202191424A1 (https=)
IL (1) IL283189A (https=)
JO (1) JOP20210111A1 (https=)
MX (1) MX2021005908A (https=)
PH (1) PH12021551119A1 (https=)
SG (1) SG11202104952PA (https=)
WO (1) WO2020104948A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA202191105A1 (ru) 2018-10-22 2021-08-03 Янссен Фармацевтика Нв Слитые белки, полученные из глюкагоноподобного пептида 1 (glp1) и ростового фактора дифференцировки 15 (gdf15), и их применение
EP4041281B1 (en) 2019-10-04 2025-11-26 Amgen Inc. Use of gdf15 for treating cardiometabolic syndrome and other conditions
WO2023154953A1 (en) 2022-02-14 2023-08-17 Ngm Biopharmaceuticals, Inc. Gdf15 polypeptides for treating and preventing autoimmune diseases

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017196647A1 (en) * 2016-05-10 2017-11-16 Janssen Biotech, Inc. Gdf15 fusion proteins and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9131966B2 (en) * 2013-03-11 2015-09-15 DePuy Synthes Products, Inc. Vertebral manipulation assembly
EP3157947A1 (en) * 2014-06-23 2017-04-26 Novartis AG Hsa-gdf-15 fusion polypeptide and use thereof
JP6946304B2 (ja) * 2015-12-22 2021-10-06 ノバルティス アーゲー 増殖分化因子15(gdf−15)を使用して代謝障害を処置するまたは軽快させる方法
EA202191105A1 (ru) * 2018-10-22 2021-08-03 Янссен Фармацевтика Нв Слитые белки, полученные из глюкагоноподобного пептида 1 (glp1) и ростового фактора дифференцировки 15 (gdf15), и их применение

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017196647A1 (en) * 2016-05-10 2017-11-16 Janssen Biotech, Inc. Gdf15 fusion proteins and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
XIONG, Y. ET AL.: "Long-acting MIC-1/GDF15 molecules to treat obesity: Evidence from mice to monkeys", SCIENCE TRANSLATIONAL MEDICINE, vol. 9, no. 412, JPN6023053167, 2017, pages 8732, ISSN: 0005227562 *

Also Published As

Publication number Publication date
JOP20210111A1 (ar) 2021-05-19
CN121818901A (zh) 2026-04-10
BR112021009225A2 (pt) 2021-10-05
AU2019383019A1 (en) 2021-06-03
KR20210094584A (ko) 2021-07-29
EP3883960A4 (en) 2022-11-09
WO2020104948A1 (en) 2020-05-28
MX2021005908A (es) 2021-09-08
PH12021551119A1 (en) 2021-11-22
AU2025202337A1 (en) 2025-04-24
US20220315633A1 (en) 2022-10-06
JP2025081388A (ja) 2025-05-27
EA202191424A1 (ru) 2021-08-24
IL283189A (en) 2021-06-30
EP3883960A1 (en) 2021-09-29
SG11202104952PA (en) 2021-06-29
CA3120236A1 (en) 2020-05-28
CN113474363A (zh) 2021-10-01

Similar Documents

Publication Publication Date Title
TW201201832A (en) Pharmaceutical composition comprising AVE0010 and insulin glargine
JP2025081388A (ja) 体重減少及び/又は食物摂取量低減に使用するためのgdf15類似体及び方法
US20220323550A1 (en) Pegloticase for treatment of gout in renal transplant recipients
ES2895513T3 (es) Tratamiento con lixisenatida de pacientes pediátricos con diabetes mellitus tipo 2
KR20170094361A (ko) 인슐린 글라진/릭시세나티드 고정비 제형
JP5197012B2 (ja) 大腸連続性を伴う短腸症候群患者の治療
US20260070997A1 (en) Cd40l-specific tn3-derived scaffolds for the treatment and prevention of sjögren's syndrome
US20260098087A1 (en) Dosages of emactuzumab
CA2868688A1 (en) Compositions, methods and assays comprising amylin or amlyin analogs for abeta-peptide mediated disorders
CA3072903A1 (en) Modified fibroblast growth factor 21 (fgf-21) for use in methods for treating nonalcoholic steatohepatitis (nash)
TWI865759B (zh) 涉及過量游離light之方法及治療
EA051453B1 (ru) Способы лечения и профилактики рассеянного склероза с применением соединений замещенного аминопиримидина
Harris CLINICAL PROTOCOL APPROVAL FORM
NZ734595B2 (en) Treatment of pediatric type 2 diabetes mellitus patients with lixisenatide
BR112017015099B1 (pt) Uso de lixisenatida e/ou um sal farmaceuticamente aceitável da mesma para tratar pacientes pediátricos portadores de diabetes mellitus tipo 2

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20211227

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221116

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221116

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231226

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240325

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240626

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20241008

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250207

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20250312